
Joseph Golec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7862847/publications.pdf Version: 2024-02-01



LOSEDH COLEC

#	Article	IF	CITATIONS
1	Do Firms Purposefully Change Capital Structure? Evidence from an Investment-Opportunity Shock to Drug Firms. Journal of Financial and Quantitative Analysis, 2021, 56, 915-944.	3.5	12
2	How excluding some benefits from value assessment of new drugs impacts innovation. Health Economics (United Kingdom), 2017, 26, 1813-1825.	1.7	3
3	Using options to measure the full value-effect of an event: Application to Obamacare. Journal of Financial Economics, 2016, 120, 169-193.	9.0	26
4	Debt Capacity of Real Estate Collateral. Real Estate Economics, 2014, 42, 578-605.	1.7	18
5	Professor John Andrew Vernon 1968–2012. Paediatric Drugs, 2012, 14, 281-281.	3.1	0
6	Do Investors See through Mistakes in Reported Earnings?. Journal of Financial and Quantitative Analysis, 2011, 46, 1917-1946.	3.5	26
7	Pharmaceutical R&D Spending and Threats of Price Regulation. Journal of Financial and Quantitative Analysis, 2010, 45, 239-264.	3.5	41
8	Strategic trading in the wrong direction by a large institutional insider. Journal of Empirical Finance, 2010, 17, 1-22.	1.8	8
9	Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms. Pharmacoeconomics, 2010, 28, 615-628.	3.3	27
10	Financial risk of the Biotech Industry versus the Pharmaceutical Industry. Applied Health Economics and Health Policy, 2009, 7, 155-165.	2.1	13
11	Mutual fund volatility timing and management fees. Journal of Banking and Finance, 2009, 33, 589-599.	2.9	25
12	Measuring US Pharmaceutical Industry R&D Spending. Pharmacoeconomics, 2008, 26, 1005-1017.	3.3	4
13	New estimates of pharmaceutical research and development spending by USâ€based firms from 1984 to 2003. Managerial and Decision Economics, 2007, 28, 481-483.	2.5	4
14	Are the Insider Trades of a Large Institutional Investor Informed?. Financial Review, 2007, 42, 161-190.	1.8	1
15	The Conditional Performance of REIT Stock Repurchases. Journal of Real Estate Finance and Economics, 2006, 32, 129-149.	1.5	6
16	Performance fee contract change and mutual fund risk. Journal of Financial Economics, 2004, 73, 93-118.	9.0	78
17	Empirical Ross recovery without discretization. Financial Review, 0, , .	1.8	0